Clinical Trials List
2020-09-01 - 2022-01-31
Phase I
Terminated1
ICD-10B33.8
Other specified viral diseases
ICD-10B34.1
Enterovirus infection, unspecified
ICD-10B34.2
Coronavirus infection, unspecified
ICD-10B34.3
Parvovirus infection, unspecified
ICD-10B34.4
Papovavirus infection, unspecified
ICD-10B34.8
Other viral infections of unspecified site
ICD-10B97.19
Other enterovirus as the cause of diseases classified elsewhere
ICD-10B97.21
SARS-associated coronavirus as the cause of diseases classified elsewhere
ICD-10B97.29
Other coronavirus as the cause of diseases classified elsewhere
ICD-10B97.5
Reovirus as the cause of diseases classified elsewhere
ICD-10B97.6
Parvovirus as the cause of diseases classified elsewhere
ICD-10B97.81
Human metapneumovirus as the cause of diseases classified elsewhere
ICD-10B97.89
Other viral agents as the cause of diseases classified elsewhere
ICD-9079.89
Other specified viral infection in conditions classified elsewhere and of unspecified site
A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901
-
Trial Applicant
Medigen Vaccine Biologics corp.
-
Sponsor
Medigen Vaccine Biologics Corp.
-
Trial scale
Taiwan Single Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- 劉旺達 Division of Infectious Disease
- Shan-Chwen Chang Division of Infectious Disease
- 黃于珊 Division of Infectious Disease
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Incidence of solicited adverse events (AEs) after vaccination, Incidence of unsolicited AEs and other AEs after vaccination, Incidence of laboratory abnormality after vaccination, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) after vaccination
Inclution Criteria
Male or female healthy volunteer ≥20 and <50 years of age
Exclusion Criteria
Receiving any investigational intervention either currently or within 30 days of first dose;
The Estimated Number of Participants
-
Taiwan
45 participants
-
Global
45 participants
